{
  "docId": "019de070-a24a-718d-8fa7-de49d427834d",
  "docSlug": "119c472f2b470327a8fb07de55a72f86",
  "documentTitle": "Alkermes | Results Presentation Deck | 15 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 15,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 18,
  "notes": "Includes footnotes explaining specific revenue fluctuations due to COVID-19 and milestone payments.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-a24a-718d-8fa7-de49d427834d/8",
  "deckHref": "/decks/019de070-a24a-718d-8fa7-de49d427834d",
  "deckJsonHref": "/decks/019de070-a24a-718d-8fa7-de49d427834d.json",
  "deckAnchorHref": "/decks/019de070-a24a-718d-8fa7-de49d427834d#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.028,
        "w": 0.362,
        "x": 0.124,
        "y": 0.914
      },
      "kind": "disclaimer",
      "text": "Amounts in the table above do not sum due to rounding.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac806d85-a589-4bb1-b81c-f382107a96db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.066,
        "w": 0.785,
        "x": 0.124,
        "y": 0.798
      },
      "kind": "source-note",
      "text": "*Decrease in VIVITROL net sales in FY 2020 was primarily due to COVID-19 pandemic-related disruptions. †Includes $5.2M of the $150M milestone payment from Biogen related to FDA approval of VUMERITY® recorded as R&D revenue. ‡Includes $144.8M of the $150M milestone payment from Biogen related to FDA approval of VUMERITY recorded as license revenue.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85f43626-508c-4621-abda-0ecda5575eaf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.556,
        "w": 0.752,
        "x": 0.124,
        "y": 0.214
      },
      "kind": "table",
      "text": "Revenue breakdown by product and category for 2020 vs 2019",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac83899e-53dd-4bf4-aefb-be6c1ce89c10",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.051,
        "w": 0.359,
        "x": 0.037,
        "y": 0.103
      },
      "kind": "title",
      "text": "2020 Revenue Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61b00f84-e198-4659-9d1b-3cc1a94770cf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 6,
      "beatId": "206865a1-63f3-4ce1-9ded-5241edbd49b9",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Financials",
      "beatSlug": "sequoia-pitch-financials",
      "evidence": "The presentation provides a detailed overview of Alkermes' financial performance",
      "position": 1,
      "confidence": 0.7,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}